Greenwich LifeSciences Inc Dossier - Source-backed chat

Greenwich LifeSciences Inc

GLSINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $17.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $254.7M

Enterprise Value $248.5M

Shares Outstanding 14.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused entirely on the development of GLSI-100 (GP2 + GM-CSF), an immunotherapy designed to prevent breast cancer recurrences. The company's investment thesis is highly binary, centered on the success of its Phase III FLAMINGO-01 trial. Recent clinical updates from the open-label non-HLA-A*02 arm have demonstrated exceptional efficacy, showing an annual recurrence rate of less than 1% (representing an ~80% reduction in recurrence rate compared to historical controls). While the company faces near-term administrative and regulatory headwinds due to delayed SEC filings (Form 10-K for 2025 and Form 10-Q for Q1 2026) stemming from auditor coordination issues, its underlying clinical fundamentals remain robust. With an unaudited cash balance of $10.5 million as of March 31, 2026, and a highly promising safety and immunogenicity profile, GLSI represents a high-risk, high-reward opportunity for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$45.00

Mean target$57.00

High · most bullish analyst$69.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

The company experiences prolonged delays in filing its SEC reports, leading to a potential Nasdaq delisting or severe loss of investor confidence. Clinical trial enrollment slows down, or interim analysis of the double-blinded HLA-A*02 arms (requiring 14 events for interim analysis) shows futility or safety concerns. The company is forced to execute highly dilutive equity raises at depressed valuations to fund ongoing Phase III operations.

Base CaseCentral scenario

$47.5050%

The company successfully files its delayed Form 10-K and Form 10-Q, resolving its Nasdaq non-compliance status without facing delisting. FLAMINGO-01 continues global site expansion (up to 190-200 sites) and maintains steady patient enrollment. Preliminary open-label data continues to trend positively, supporting the biological mechanism of action, while the company utilizes its at-the-market (ATM) financing facility to manage cash burn.

Bull CaseUpside scenario

$50.0030%

The Phase III FLAMINGO-01 trial meets its primary endpoints with high statistical significance, demonstrating a hazard ratio of 0.3 or better in invasive breast cancer-free survival. Regulatory agencies approve the expansion of the non-HLA-A*02 arm into a randomized controlled trial, effectively doubling the addressable patient population. The company secures a lucrative co-development or licensing partnership with a major pharmaceutical firm, providing non-dilutive funding and commercialization infrastructure.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase IIb clinical data showing 0% recurrences over 5 years of follow-up in HER2/neu 3+ patients who completed the full treatment series.
Highly encouraging preliminary Phase III open-label data in the non-HLA-A*02 arm, showing a recurrence rate of less than 1% per year and an ~80% reduction in recurrence rate compared to historical standard-of-care controls.
FDA Fast Track designation for GLSI-100 in HLA-A*02-positive and HER2-positive breast cancer, facilitating expedited development and potential rolling BLA submission.
Significant expansion of clinical trial sites, including the addition of prestigious institutions like City of Hope and planned expansions in Europe, the UK, and Canada.

Key Investment Risks

Binary risk profile with a single pipeline asset (GLSI-100), leaving no fallback options if the Phase III trial fails.
Regulatory and compliance risks associated with the delayed filing of the 2025 Form 10-K and Q1 2026 Form 10-Q, which has triggered Nasdaq non-compliance notices.
Financial constraints and potential dilution risk, as the clinical-stage company is pre-revenue and relies on financing to fund expensive global Phase III trials.
Lack of a direct placebo control group in the open-label non-HLA-A*02 arm, making historical comparisons (e.g., to the KATHERINE trial) imperfect.

Thesis Invalidation Triggers

Futility or safety-related halt of the FLAMINGO-01 trial during the planned interim analysis (at 14 events).
Failure to regain compliance with Nasdaq listing requirements, resulting in delisting to over-the-counter (OTC) markets.
Inability to secure additional capital or regulatory approval to continue enrolling non-HLA-A*02 patients in a randomized controlled manner.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.